References
- Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–10.
- Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028–40.
- Deng YL, Xiong XZ, Cheng NS. Organ fibrosis inhibited by blocking transforming growth factor-beta signaling via peroxisome proliferator-activated receptor gamma agonists. Hepatobiliary Pancreat Dis Int 2012;11:467–78.
- Friedman SL, Sheppard D, Duffield JS, et al. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013;5:167.
- Fang F, Liu L, Yang Y, et al. The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. Arthritis Res Ther 2012;14:R229.
- Mishra R, Cool BL, Laderoute KR, et al. AMP-activated protein kinase inhibits transforming growth factor-beta-induced Smad3-dependent transcription and myofibroblast transdifferentiation. J Biol Chem 2008;283:10461–9.
- Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746–9.
- Handy JA, Fu PP, Kumar P, et al. Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 2012;440:385–95.
- Otvos L Jr, Haspinger E, Russa FL, et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol 2011;11:90.
- Miele M, Costantini S, Colonna G. Structural and functional similarities between osmotin from Nicotiana tabacum seeds and human adiponectin. PLoS One 2011;6:2.
- Yamauchi T, Iwabu M, Okada-Iwabu M, et al. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 2013;28:15–23.
- Zoete V, Grosdidier A, Michielin O. Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med 2009;13:238–48.
- Kellenberger E, Rodrigo J, Muller P, et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004;57:225–42.
- Shen MY, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci 2006;15:2507–24.
- Lovell SC, Davis IW, Arendall WB, et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 2003;50:437–50.
- Chen ZJ, Jin W, Liu H, et al. Discovery of peptide ligands for hepatic stellate cells using phage display. Mol Pharm 2015;12:2180–8.
- Wallace MC, Friedman SL. Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development. Gene Expres 2014;16:77–84.
- Leibiger C, Kosyakova N, Mkrtchyan H, et al. First molecular cytogenetic high resolution characterization of the NIH 3T3 cell line by murine multicolor banding. J Histochem Cytochem 2013;61:306–12.
- Jainchill JL, Aaronson SA, Todaro GJ. Murine Sarcoma and Leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 1969;4:549–53.
- Otvos L Jr, Wade JD. Current challenges in peptide-based drug discovery. Front Chem 2014;2:62.
- Wang HF, Zhang H, Zhang ZM, et al. Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury. Sci Rep 2016;6:19445.
- Kumar P, Smith T, Rahman K, et al. Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS One 2014;9:e110405.
- Tsai TH, Ma HI, Liu MY. Pigment epithelium-derived factor 34-mer peptide prevents liver fibrosis and hepatic stellate cell activation through down-regulation of the PDGF receptor. PLoS One 2014;9:e95443.
- Tang Y, Hu C, Liu Y. Effect of bioactive peptide of Carapax Trionycis on TGF-β1-induced intracellular events in hepatic stellate cells. J Ethnopharmacol 2013;148:69–73.
- Lopez-Mejia IC, Fajas L. Cell cycle regulation of mitochondrial function. Curr Opin Cell Biol 2015;33:19–25.
- Novo E, Cannito S, Paternostro C, et al. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys 2014;548:20–37.
- Dees C, Distler JHW. Canonical Wnt signalling as a key regulator of fibrogenesis – implications for targeted therapies? Exp Dermatol 2013;22:710–13.
- Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002;7:d793–807.
- Biancheri P, Giuffrida P, Docena GH, et al. The role of transforming growth factor (TGF)-β in modulating the immune response and fibrogenesis in the gut. Cytokine Growth Factor Rev 2014;25:45–55.
- Meng XM, Tang PM, Li J, et al. TGF-β/Smad signaling in renal fibrosis. Front Physiol 2015;6:82.